carbamates has been researched along with Exanthem in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To report successful desensitization to amprenavir after the occurrence of a maculopapular exanthem in an HIV-infected patient with late-stage disease and limited antiretroviral treatment options." | 7.73 | Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus. ( Huynh, P; Kohli-Pamnani, A; Lobo, F, 2006) |
| "To report successful desensitization to amprenavir after the occurrence of a maculopapular exanthem in an HIV-infected patient with late-stage disease and limited antiretroviral treatment options." | 3.73 | Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus. ( Huynh, P; Kohli-Pamnani, A; Lobo, F, 2006) |
| " Safety was monitored as clinical adverse events (AEs) and laboratory abnormalities." | 2.70 | Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. ( Lloyd, PP; Lou, Y; Piliero, PJ; Preston, SL; Sadler, BM; Stein, DS, 2001) |
| "Amprenavir (APV) is a new HIV-I protease inhibitor used in combination with other antiretroviral agents for the treatment of HIV-1 infection." | 2.69 | Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection. ( Brothers, C; Fetter, A; Millard, J; Pagano, G; Pedneault, L; Tymkewycz, P; Yeo, J, 2000) |
| "Fosamprenavir is a protease inhibitor (PI) approved for the treatment of HIV-1 infection." | 2.44 | Fosamprenavir calcium plus ritonavir for HIV infection. ( Arduino, RC; Torres, HA, 2007) |
| " We evaluated dosage and serum levels, efficacy, drug interactions, and adverse effects." | 1.72 | Initial Real-World Experience With Cenobamate in Adolescents and Adults: A Single Center Experience. ( Elliott, T; Gienapp, AJ; Ridley-Pryor, T; Wheless, JW, 2022) |
| "Encorafenib is a BRAF inhibitor increasingly used as a second-line treatment for metastatic melanoma and colorectal cancer." | 1.72 | Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases. ( Alfallouji, Y; Borysiewicz, C; Bunker, CB; Calonje, E; Hodgkinson, T; Perrett, CM; Sidwell, RU; Spencer, A; Wasan, H; Watchorn, R, 2022) |
| "The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies." | 1.46 | Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study. ( Chae, HB; Cho, BW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Lee, BS; Lee, SH; Lee, TH; Song, IH, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elliott, T | 1 |
| Ridley-Pryor, T | 1 |
| Gienapp, AJ | 1 |
| Wheless, JW | 1 |
| Alfallouji, Y | 1 |
| Spencer, A | 1 |
| Calonje, E | 1 |
| Perrett, CM | 1 |
| Watchorn, R | 1 |
| Borysiewicz, C | 1 |
| Hodgkinson, T | 1 |
| Wasan, H | 1 |
| Bunker, CB | 1 |
| Sidwell, RU | 1 |
| Sankhyan, P | 1 |
| Gonzalez-Estrada, A | 1 |
| Cho, BW | 1 |
| Kim, SB | 1 |
| Song, IH | 1 |
| Lee, SH | 1 |
| Kim, HS | 1 |
| Lee, TH | 1 |
| Kang, YW | 1 |
| Kim, SH | 1 |
| Lee, BS | 1 |
| Chae, HB | 1 |
| Rojas, P | 1 |
| Sánchez, L | 1 |
| Santos, A | 1 |
| Góõmez, MP | 1 |
| Blanco, H | 1 |
| Laguna, JJ | 1 |
| Kohli-Pamnani, A | 1 |
| Huynh, P | 1 |
| Lobo, F | 1 |
| Torres, HA | 1 |
| Arduino, RC | 1 |
| Pedneault, L | 1 |
| Brothers, C | 1 |
| Pagano, G | 1 |
| Tymkewycz, P | 1 |
| Yeo, J | 1 |
| Millard, J | 1 |
| Fetter, A | 1 |
| Sadler, BM | 1 |
| Piliero, PJ | 1 |
| Preston, SL | 1 |
| Lloyd, PP | 1 |
| Lou, Y | 1 |
| Stein, DS | 1 |
1 review available for carbamates and Exanthem
| Article | Year |
|---|---|
Fosamprenavir calcium plus ritonavir for HIV infection.
Topics: Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Exanthema; | 2007 |
2 trials available for carbamates and Exanthem
| Article | Year |
|---|---|
Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection.
Topics: Adolescent; Adult; Anti-HIV Agents; Carbamates; Child; Child, Preschool; Digestive System; Drug Ther | 2000 |
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.
Topics: Administration, Oral; Adult; Body Mass Index; Carbamates; Diarrhea; Dose-Response Relationship, Drug | 2001 |
7 other studies available for carbamates and Exanthem
| Article | Year |
|---|---|
Initial Real-World Experience With Cenobamate in Adolescents and Adults: A Single Center Experience.
Topics: Adolescent; Anticonvulsants; Carbamates; Chlorophenols; Double-Blind Method; Drug-Related Side Effec | 2022 |
Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Colonic Neoplasms; Exanthema; Humans; Mu | 2022 |
Mixed Essential Cryoglobulinemia.
Topics: Antiviral Agents; Carbamates; Cryoglobulinemia; Exanthema; Hepatitis C; Heterocyclic Compounds, 4 or | 2017 |
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Dru | 2017 |
Hypersensitivity to repaglinide.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Erythema; Exanthema; Hum | 2011 |
Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus.
Topics: Adult; Carbamates; Desensitization, Immunologic; Drug Hypersensitivity; Exanthema; Female; Furans; H | 2006 |
Amprenavir: a new HIV protease inhibitor.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Carbamates; Child; Clinical Trials as Topi | 1999 |